Showing promise in the landscape of excess body fat treatment, retatrutide represents a distinct approach. Unlike many existing medications, retatrutide operates as a dual agonist, simultaneously engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) receptors. This simultaneous activation fosters more info mu